MBTPS1 and hepatocellular carcinoma: Patients with advanced CCA partially responded to S1P inhibitor ABC294640 treatment in a Phase I clinical trial [75], while a Phase I/IIA trial in iCCA (NCT03377179) and a Phase II trial in HCC (NCT02939807) are ongoing.